| Title |
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, September 2011
|
| DOI | 10.2147/ndt.s24196 |
| Pubmed ID | |
| Authors |
Åsa K Wallin, Carina Wattmo, Lennart Minthon |
| Abstract |
In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors in Alzheimer's disease (AD), analysis of the results of open-label trials becomes crucial. This study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of response and adherence to treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Netherlands | 1 | 1% |
| Unknown | 78 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 17% |
| Researcher | 11 | 14% |
| Student > Master | 9 | 11% |
| Student > Bachelor | 9 | 11% |
| Student > Doctoral Student | 4 | 5% |
| Other | 14 | 17% |
| Unknown | 20 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 32% |
| Psychology | 10 | 12% |
| Agricultural and Biological Sciences | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 11 | 14% |
| Unknown | 22 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2023.
All research outputs
#3,415,054
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#493
of 3,132 outputs
Outputs of similar age
#17,309
of 136,084 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#4
of 13 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 136,084 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.